Cancer treatments http://www.globalpost.com/taxonomy/term/31876/all en Genetically engineered virus kills cancer: study http://www.globalpost.com/dispatch/news/afp/130210/genetically-engineered-virus-kills-cancer-study <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.</p> <p>Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose.</p> <p>"For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients," study co-author David Kirn told AFP.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130210/genetically-engineered-virus-kills-cancer-study" target="_blank">read more</a></p> Cancer treatments Entertainment Management of cancer Medicine Technology AFP Sun, 10 Feb 2013 18:17:48 +0000 5751964 at http://www.globalpost.com Chavez's 20-month battle against cancer http://www.globalpost.com/dispatch/news/afp/130304/chavezs-20-month-battle-against-cancer <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Venezuelan President Hugo Chavez has suffered a setback, the government said late Monday, with a "new and severe" infection as he undergoes the latest round of intensive chemotherapy in his 20-month battle with cancer.</p> <p>--2011--</p> <p>- June 10: Chavez undergoes surgery in Cuba to treat an abscess in his pelvic area.</p> <p>- June 30: Chavez discloses that he underwent surgery to remove a malignant tumor.</p> <p>- October 20: Chavez declares he is free of cancer after four rounds of chemotherapy.</p> <p>--2012--</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130304/chavezs-20-month-battle-against-cancer" target="_blank">read more</a></p> Cancer treatments Che Guevara Health Hugo Chavez Venezuela AFP Tue, 05 Mar 2013 04:46:04 +0000 5773504 at http://www.globalpost.com Never-ending ordeal for Romanian cancer patients http://www.globalpost.com/dispatch/news/afp/130315/never-ending-ordeal-romanian-cancer-patients <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>"Fighting cancer is a daily battle," says Camelia Dima, whose daughter suffers from a malignant tumour. But in Romania, long waiting lists and a shortage of drugs make the fight even harder.</p> <p>"Europe is characterised by worrying inequalities in cancer control and care", the European Commission recently warned.</p> <p>With a 2013 budget accounting for barely 4.5 percent of gross domestic product - less than half the European Union average - Romania's health system is in a critical condition.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130315/never-ending-ordeal-romanian-cancer-patients" target="_blank">read more</a></p> Cancer treatments Health Human Interest Medicine AFP Fri, 15 Mar 2013 05:30:36 +0000 5784158 at http://www.globalpost.com FDA advisers vote against Delcath's cancer therapy http://www.globalpost.com/dispatch/news/thomson-reuters/130515/fda-advisers-recommend-against-delcaths-cancer-therapy <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - A panel of advisers to the U.S. health regulator said that risks outweighed the benefits in Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver.</p> <p>The panel of independent experts voted 16-0 against the drug/device combination.</p> <p>The drug-device combination product consists of a chemotherapy drug, melphalan hydrochloride, and a device known as the Delcath Hepatic Delivery System. The two are combined in a single package known as the Melblez Kit.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130515/fda-advisers-recommend-against-delcaths-cancer-therapy" target="_blank">read more</a></p> Alkylating antineoplastic agents Cancer treatments Health Medicine Pharmacology Technology Thomson Reuters Wed, 15 May 2013 18:32:48 +0000 5838500 at http://www.globalpost.com Immunotherapy is not just for melanoma anymore http://www.globalpost.com/dispatch/news/thomson-reuters/130531/immunotherapy-not-just-melanoma-anymore <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Julie Steenhuysen and Deena Beasley</p> <p>CHICAGO/LOS ANGELES (Reuters) - Diagnosed with advanced lung cancer over a year ago, Gabe Tartaglia was loath to undergo the kind of harsh chemotherapy that had devastated his sister before her death three years earlier from pancreatic cancer.</p> <p>He decided to enter a clinical trial for a new drug designed to trigger the immune system to fight cancer. The results were better than anyone expected.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130531/immunotherapy-not-just-melanoma-anymore" target="_blank">read more</a></p> Cancer treatments Medicine Ribbon symbolism Technology Thomson Reuters Fri, 31 May 2013 05:31:30 +0000 5849245 at http://www.globalpost.com Targeting lung cancer genes improves outcome http://www.globalpost.com/dispatch/news/afp/130601/targeting-lung-cancer-genes-improves-outcome <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Lung cancer patients who received a drug designed to target a genetic dysfunction lived longer with fewer side effects than those who received traditional chemotherapy, a study showed Saturday.</p> <p>Researchers found that patients with an abnormal ALK gene who received Pfizer's targeted drug crizotinib remained cancer-free for nearly five months longer.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130601/targeting-lung-cancer-genes-improves-outcome" target="_blank">read more</a></p> Cancer treatments Lung cancer Medicine AFP Sat, 01 Jun 2013 17:33:56 +0000 5850043 at http://www.globalpost.com Merck melanoma drug shrinks tumors in 38 percent of patients http://www.globalpost.com/dispatch/news/thomson-reuters/130602/merck-melanoma-drug-shrinks-tumors-38-percent-patients <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Julie Steenhuysen</p> <p>CHICAGO (Reuters) - A Merck &amp; Co drug designed to unmask tumor cells and mobilize the immune system into fighting cancer helped shrink tumors in 38 percent of patients with advanced melanoma in an early-stage study, U.S. researchers said on Sunday.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130602/merck-melanoma-drug-shrinks-tumors-38-percent-patients" target="_blank">read more</a></p> Cancer treatments Medicine Melanoma Thomson Reuters Sun, 02 Jun 2013 21:01:10 +0000 5850399 at http://www.globalpost.com Canada-U.S. team develops promising 'sharp-shooter' drug aimed at several cancers http://www.globalpost.com/dispatch/news/the-canadian-press/130618/canada-us-team-develops-promising-sharp-shooter-drug-aimed-a <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> The Canadian Press </div> </div> </div> <!--paging_filter--><p>TORONTO - A team of Canadian and U.S. researchers has developed a new "sharp-shooter" drug they hope may be a breakthrough in treating several types of aggressive cancer.</p> <p>The drug, known for now as CFI-400945, is a new class of cancer agent that targets an enzyme involved in some malignancies, among them certain types of breast cancer, and ovarian, colorectal, pancreatic and prostate cancers.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.globalpost.com/terms-use#cp">Copyright 2013 Canadian Press.</a></p> <p>All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.</p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/the-canadian-press/130618/canada-us-team-develops-promising-sharp-shooter-drug-aimed-a" target="_blank">read more</a></p> Business Cancer treatments Medicine Oncology Technology The Canadian Press Tue, 18 Jun 2013 19:33:23 +0000 5860454 at http://www.globalpost.com Largest cancer gene database made public http://www.globalpost.com/dispatch/news/thomson-reuters/130715/largest-cancer-gene-database-made-public <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Deena Beasley</p> <p>(Reuters) - National Cancer Institute scientists have released the largest-ever database of cancer-related genetic variations, providing researchers the most comprehensive way so far to figure out how to target treatments for the disease.</p> <p>Open access worldwide to the new database, based on genome studies, is expected to help researchers accelerate development of new drugs and better match patients with therapies, NCI said in a statement on Monday.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130715/largest-cancer-gene-database-made-public" target="_blank">read more</a></p> Cancer organizations Cancer treatments Medicine Technology Thomson Reuters Tue, 16 Jul 2013 00:32:16 +0000 5884785 at http://www.globalpost.com Pet pig Nemo's lymphoma treatment makes research history http://www.globalpost.com/dispatch/news/thomson-reuters/130724/pet-pig-nemos-lymphoma-treatment-makes-research-history <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Yasmeen Abutaleb</p> <p>WASHINGTON (Reuters) - When George Goldner went to feed his six pet pigs earlier this year, his 730-pound (331-kg) companion Nemo was acting strangely. Nemo had suddenly stopped eating and laid in the mud.</p> <p>So Goldner loaded Nemo into a trailer and drove more than two hours to Cornell University Hospital for Animals (CUHA) in Ithaca, New York. There he learned his four-year-old Hampshire pig had what doctors believed was the blood cancer B-cell lymphoma.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130724/pet-pig-nemos-lymphoma-treatment-makes-research-history" target="_blank">read more</a></p> Cancer treatments Chemotherapy George Goldner Lymphoma Thomson Reuters Wed, 24 Jul 2013 19:02:50 +0000 5892701 at http://www.globalpost.com Incyte pancreatic cancer drug improves survival in mid-stage trial http://www.globalpost.com/dispatch/news/thomson-reuters/130821/incyte-pancreatic-cancer-drug-improves-survival-mid-stage-trial <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - Incyte Corp reported an improved survival rate in patients most likely to benefit from its experimental pancreatic cancer treatment, Jakafi, sending the company's shares up 30 percent to its highest in almost 13 years.</p> <p>Analysts said the data from a mid-stage trial suggested that the drug, already approved in the U.S. to treat a form of blood cancer, can work in a late-stage pancreatic cancer study, as well as on other cancerous tumors.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130821/incyte-pancreatic-cancer-drug-improves-survival-mid-stage-trial" target="_blank">read more</a></p> Cancer treatments Medicine Organofluorides Thomson Reuters Wed, 21 Aug 2013 15:46:00 +0000 5914530 at http://www.globalpost.com AstraZeneca bets on combinations in cancer immunotherapy race http://www.globalpost.com/dispatch/news/thomson-reuters/131014/astrazeneca-bets-combinations-cancer-immunotherapy-race <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Ben Hirschler</p> <p>LONDON (Reuters) - AstraZeneca is betting on drug combinations to help it catch up with industry leaders in the race to develop new treatments that harness the body's immune system to fight cancer.</p> <p>Bristol-Myers Squibb, Roche and Merck &amp; Co are currently out in front with such immunotherapies, which analysts believe may extend patients' lives significantly and generate tens of billions of dollars in annual sales.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131014/astrazeneca-bets-combinations-cancer-immunotherapy-race" target="_blank">read more</a></p> Cancer treatments Chemistry Medicine Technology Thomson Reuters Mon, 14 Oct 2013 16:32:12 +0000 5960608 at http://www.globalpost.com Curis cancer drug put on partial hold after patient death http://www.globalpost.com/dispatch/news/thomson-reuters/131106/curis-cancer-drug-put-partial-hold-after-patient-death <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - Curis Inc said it had been stopped from enrolling any new patients in an early stage trial of its experimental cancer drug following the death of a patient who had liver failure.</p> <p>Curis's shares fell 10 percent in premarket trading after the U.S. Food and Drug Administration placed a partial hold on the trial.</p> <p>The company said the FDA was seeking additional data on patients treated with the drug, CUDC-427.</p> <p>Curis said it expects to respond to the agency's requests in a timely manner.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131106/curis-cancer-drug-put-partial-hold-after-patient-death" target="_blank">read more</a></p> Breast cancer Cancer treatments Curis Inc Ribbon symbolism Thomson Reuters Wed, 06 Nov 2013 13:49:36 +0000 5981653 at http://www.globalpost.com Childhood cancer survivors face heart risks soon after treatment http://www.globalpost.com/dispatch/news/thomson-reuters/131117/childhood-cancer-survivors-face-heart-risks-soon-after-treatmen <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Bill Berkrot and Ransdell Pierson</p> <p>DALLAS (Reuters) - Children who survive cancer treatment face increased heart health risk and should take measures soon after life-saving therapy to reduce the risk of serious problems later in life, according to research presented at a major medical meeting.</p> <p>The five-year survival rate from childhood cancer has soared from 58 percent in 1975 to 1977, to 83 percent in the period from 2003 to 2009.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131117/childhood-cancer-survivors-face-heart-risks-soon-after-treatmen" target="_blank">read more</a></p> Cancer treatments Health Labor Medicine Oncology Social Issues Thomson Reuters Sun, 17 Nov 2013 19:48:52 +0000 5991767 at http://www.globalpost.com Merck trial shows more melanoma cancer patients respond to drug http://www.globalpost.com/dispatch/news/thomson-reuters/131118/merck-trial-shows-more-melanoma-cancer-patients-respond-drug <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - Early data from a small trial of Merck &amp; Co Inc's experimental immunotherapy cancer drug, known as MK-3475, show that about half of advanced melanoma patients treated with the highest dose of the drug experienced tumor shrinkage.</p> <p>Updated results from the early-stage trial are set to be presented on Monday at the International Congress of the Society for Melanoma Research in Philadelphia.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131118/merck-trial-shows-more-melanoma-cancer-patients-respond-drug" target="_blank">read more</a></p> Cancer treatments Medicine Melanoma Thomson Reuters Mon, 18 Nov 2013 17:34:31 +0000 5992588 at http://www.globalpost.com